Journal of the American Herbalist Guild Vol 6 issue 1
The safety and efficacy of a Boswellia extract was compared against mesalazine for the treatment of 102 patients with active Crohn's disease in an eight-week randomized, double blind European study. The primary clinical outcome measured was the change in Crohn's Disease Activity Index (CDAI). After therapy with Boswellia extract (3.6 g per day) the average CDAI was reduced by 90, compared to a reduction of 53 for the mesalazine group (4.5 g per day).
The authors concluded that the Boswellia extract was as effective as mesalazine, which is the current treatment for this disorder. Considering the observed fewer side effects and better safety profile of Boswellia, they suggested that his novel herbal treatment appears to be superior to mesalazine in terms of a risk-benefit evaluation.